share_log

Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target

Benzinga Real-time News ·  Jul 26, 2022 08:14

Maxim Group analyst Naz Rahman upgrades Agile Therapeutics (NASDAQ:AGRX) from Hold to Buy and announces $1 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment